Looking for a reliable flashlight that will stand up to daily use? You might consider picking up a model that's actually endorsed for use by the FBI.
A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in yellow) inhibits ...
Reducing the time and expense of engineering PROTAC degraders remains a significant challenge in the pharmaceutical industry. A PROTAC is composed of an E3 ligase ligand (E3-L), a protein of interest ...
Pfizer, Arvinas lose interest in commercializing PROTAC inhibitor, leading to layoffs at the biotech
Having already stripped back their development plans for the estrogen receptor (ER) degrader vepdegestrant on the back of mixed data, Pfizer and Arvinas have now decided to wash their hands of the ...
As an added bonus, ProTac can be set to a "flicker mode" in which the PDLC continuously (and rapidly) switches back and forth between its transparent and opaque states. This allows the system to ...
Conceptual overview of the vision-based ProTac sensing technology. ProTac can actively switch between proximity and tactile sensing modes, relying on input images captured by inner cameras and a soft ...
Noelle Acheson outlines the key blockchain innovations for payment programmability, and highlights their advantages and their risks. By redistributing creativity and responsibility, blockchains can ...
The end of the undruggable: Targeted protein degradation therapies open new frontiers in cancer care
Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments. Based on a cell’s natural mechanism for eliminating diseased proteins, this therapy can combat hard-to-treat ...
EAGLEVILLE, PA - Streamlight Inc., a leading provider of high-performance lighting, introduced the ProTac 2.0 HP tactical flashlight, delivering 85,000 candela for powerful downrange illumination, ...
In this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer who had received one previous line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results